Gregory D. Kutz , Managing Director, Forensic Audits and Special Investigations (FSI), U.S. Government Accountability Office (Click here to view statement - PDF)

Dr. Kathy Hudson , Director, Genetics & Public Policy Center, Johns Hopkins University Berman Bioethics Institute (Click here to view statement - PDF)

Panel 2

Rosalynn Gill-Garrison , Chief Science Officer, Sciona, Boulder, CO (Click here to view statement - PDF)

Carol Reed , VP and Chief Medical Officer, Genaissance Pharmaceuticals, Newton, MA, with labs in Connecticut and North Carolina (Click here to view statement - PDF)

Kristopher King , CEO, Suracell, Montclair, NJ (Click here to view statement - PDF)

Rama Rathnam , President, Genox, Baltimore, MD (Click here to view statement - PDF)

Howard Coleman , CEO, Genelex Corporation, Seattle, WA (Click here to view statement - PDF)

Panel 3

Thomas Hamilton , Director, Survey and Certification Group, Centers for Medicare and Medicaid Services (CMS) (Click here to view statement - PDF)

Steven M. Gutman , MD, Director, Office of in Vitro Diagnostic Devices, Food and Drug Administration (FDA) (Click here to view statement - PDF)